Journal article · 2025 · Open access
Alzheimer's disease drug development pipeline: 2025
Alzheimer s & Dementia Translational Research & Clinical Interventions, 11(2), e70098 · Published 1 April 2025 · DOI 10.1002/trc2.70098
In brief
“Alzheimer's disease drug development pipeline: 2025” is a 2025 journal article by Jeffrey L. Cummings and 6 co-authors, published in Alzheimer s & Dementia Translational Research & Clinical Interventions. OpenAlex counts 262 citations as of 15 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Alzheimer s & Dementia Translational Research & Clinical Interventions.
- Citations
- 262
- Most cited in
- 2026 (200)
- Field-weighted impact
- 72.06
- References
- 16
- Authors
- 7
Abstract
Clinical trials for Alzheimer's disease (AD) must be registered on clinicaltrials.gov. The registry presents a variety of types of information related to the planned clinical trial. We assess clinicaltrials.gov to document and compare aspects of drug development across the AD pipeline. Currently, there are 138 drugs being assessed in 182 clinical trials in the AD pipeline. Biological disease-targeted therapies (DTTs) comprise 30% of the pipeline; small molecule DTTs account for 43% of the pipeline; drugs addressing cognitive enhancement account for 14% of the pipeline; and drugs aiming to ameliorate neuropsychiatric symptoms in participants with AD contribute 11% of the pipeline. Biomarkers are among the primary outcomes of 27% of active trials. Repurposed agents represent 33% of the pipeline agents. The pipeline has more trials and more drugs compared to the 2024 pipeline. Highlights: The 2025 Alzheimer's disease drug development pipeline hosts 182 trials and 138 novel drugs.The 2025 Alzheimer's disease drug development pipeline is diverse, with agents that address 15 basic disease processes.The 2025 Alzheimer's disease drug development pipeline has more trials and more drugs than the 2024 pipeline.Biomarkers play an important role in current trials to determine trial eligibility and as outcomes of trials.Repurposed agents comprise approximately one-third of the agents and trials in the 2025 Alzheimer's disease drug development pipeline.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Cummings, J. L., Zhou, Y., Lee, G., Zhong, K., Cacho, J. R. F., Osse, A. M. L., & Cheng, F. (2025). Alzheimer's disease drug development pipeline: 2025. Alzheimer s & Dementia Translational Research & Clinical Interventions, 11(2), e70098. https://doi.org/10.1002/trc2.70098
MLA 9
Cummings, Jeffrey L., et al. “Alzheimer's disease drug development pipeline: 2025.” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 11, no. 2, 2025, p. e70098. https://doi.org/10.1002/trc2.70098.
Chicago
Cummings, Jeffrey L., Yadi Zhou, Garam Lee, Kate Zhong, Jorge Ramón Fonseca Cacho, Amanda M. Leisgang Osse, and Feixiong Cheng. 2025. “Alzheimer's disease drug development pipeline: 2025.” Alzheimer s & Dementia Translational Research & Clinical Interventions 11 (2): e70098. https://doi.org/10.1002/trc2.70098.
Harvard
Cummings, J. L. et al. (2025) ‘Alzheimer's disease drug development pipeline: 2025’, Alzheimer s & Dementia Translational Research & Clinical Interventions, 11(2), p. e70098. doi:10.1002/trc2.70098.
IEEE
J. L. Cummings et al., “Alzheimer's disease drug development pipeline: 2025,” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 11, no. 2, p. e70098, 2025, doi: 10.1002/trc2.70098.
BibTeX
@article{cummings2025alzheimer,
title = {{Alzheimer's disease drug development pipeline: 2025}},
author = {Cummings, Jeffrey L. and Zhou, Yadi and Lee, Garam and Zhong, Kate and Cacho, Jorge Ramón Fonseca and Osse, Amanda M. Leisgang and Cheng, Feixiong},
journal = {Alzheimer s \& Dementia Translational Research \& Clinical Interventions},
year = {2025},
volume = {11},
number = {2},
pages = {e70098},
doi = {10.1002/trc2.70098},
url = {https://doi.org/10.1002/trc2.70098}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Alzheimer's disease
- drug development pipeline
- clinical trials
- ClinicalTrials.gov
- small molecule drugs
- cognitive enhancement
- neuropsychiatric symptoms
- biomarkers
Work with this paper
Most-cited papers in Neuroscience
- The Rat Brain in Stereotaxic CoordinatesGeorge Paxinos, CHARLES R. R. WATSON · Elsevier eBooks · 1982 · 52,413 citations
- The assessment and analysis of handedness: The Edinburgh inventoryRichard Charles Oldfield · Neuropsychologia · 1971 · 36,725 citations
- EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysisArnaud Delorme A, Scott Makeig · Journal of Neuroscience Methods · 2004 · 25,302 citations
- The Ecological Approach to Visual PerceptionMarc H. Bornstein, James J. Gibson · Journal of Aesthetics and Art Criticism · 1980 · 22,977 citations
- The Psychophysics ToolboxDavid H. Brainard · Spatial Vision · 1997 · 20,208 citations
Questions about this paper
How do I cite this paper in APA style?
Cummings, J. L., Zhou, Y., Lee, G., Zhong, K., Cacho, J. R. F., Osse, A. M. L., & Cheng, F. (2025). Alzheimer's disease drug development pipeline: 2025. Alzheimer s & Dementia Translational Research & Clinical Interventions, 11(2), e70098. https://doi.org/10.1002/trc2.70098
How many times has this paper been cited?
262 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Alzheimer s & Dementia Translational Research & Clinical Interventions.
Who wrote this paper?
Jeffrey L. Cummings, Yadi Zhou, Garam Lee, Kate Zhong, Jorge Ramón Fonseca Cacho, Amanda M. Leisgang Osse, Feixiong Cheng.
What is the DOI of this paper?
10.1002/trc2.70098. The permanent link is https://doi.org/10.1002/trc2.70098.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.